circCDK13-loaded small extracellular vesicles accelerate healing in preclinical diabetic wound models.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 38724502.
- Also identified by DOI 10.1038/s41467-024-48284-3 and PMC identifier 11082226.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Chronic wounds are a major complication in patients with diabetes. Here, we identify a therapeutic circRNA and load it into small extracellular vesicles (sEVs) to treat diabetic wounds in preclinical models. We show that circCDK13 can stimulate the proliferation and migration of human dermal fibroblasts and human epidermal keratinocytes by interacting with insulin-like growth factor 2 mRNA binding protein 3 in an N6-Methyladenosine-dependent manner to enhance CD44 and c-MYC expression. We engineered sEVs that overexpress circCDK13 and show that local subcutaneous injection into male db/db diabetic mouse wounds and wounds of streptozotocin-induced type I male diabetic rats could accelerate wound healing and skin appendage regeneration. Our study demonstrates that the delivery of circCDK13 in sEVs may present an option for diabetic wound treatment.
Medical subject headings
- Diabetes Mellitus, Experimental
- Extracellular Vesicles
- Fibroblasts
- Keratinocytes
- RNA, Circular
- Wound Healing